Pet owner Judy Bernath loves her 11-year-old cat Billy, so when she noticed he had become lethargic, started losing weight and drastically changed from the happy cat he had once been, she made a visit to see her veterinarian Dr. David Bruyette, medical director at VCA West Los Angeles Animal Hospital. The VCA team diagnosed Billy as being hyperthyroid within a few days, and Dr. Bruyette shared conventional therapy options with Judy, like radiation therapy, daily pharmaceuticals and surgery. In addition, he discussed and ultimately recommended a new and different approach for Billy’s case – nutritional management.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51765-hills-pet-nutrition-launches-new-pet-food-for-hyperthyroid-cats
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company’s novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only treatment approved by the U.S. Food and Drug Administration for CDI. The article titled,
Boehringer Ingelheim Pharmaceuticals, Inc. and CancerCare® today announced the launch of My Cancer Circle™ (www.MyCancerCircle.net), a free, private, customizable online tool that enables caregivers of people facing cancer to organize and coordinate a circle of family members and friends to provide practical and emotional support. MyCancerCircle.net will provide caregivers of people facing cancer a simple, effective answer to a question they are asked constantly, “What can we do to help?”
To view Multimedia News Release, go to http://www.multivu.com/mnr/56339-boehringer-ingelheim-cancercare-my-cancer-circle-online-tool-caregivers
Boehringer Ingelheim Pharmaceuticals, Inc. y la Comisión Latina sobre el SIDA anunciaron hoy el lanzamiento del sitio web Mente, Cuerpo, HAART™ (MenteCuerpoHAART.com), un recurso en línea en español para los latinos que viven con el VIH, para proveedores de servicios de salud y para educadores de la salud. El sitio ofrece herramientas y consejos útiles sobre cómo mantener el bienestar mental, físico y emocional ante los desafíos diarios de la enfermedad.
Para ver más comunicado de prensa multimedios, visite http://multivu.prnewswire.com/mnr/boehringeringelheim/46494/
A new survey from Alcon, the global leader in eye care and a division of Novartis, demonstrates that people experience significant emotional and lifestyle benefits after cataract surgery. Nearly three in four respondents who expressed an opinion agreed that after having the surgery, they were happier, more satisfied and had a greater appreciation for life. The survey also confirmed that life before surgery posed several daily challenges. A majority of survey respondents said cataracts made simple, day-to-day tasks harder, and made them feel annoyed, frustrated and old.
In recognition of Cataract Awareness Month this June, Alcon conducted the MyCataracts survey with 1,300 US adults, age 60 and over, who have undergone cataract surgery, to better understand the emotional journey of the condition and the lifestyle benefits of treatment. The survey expands Alcon’s ongoing MyCataracts awareness campaign by uncovering insights that will help people make informed treatment decisions together with their doctors.
To view the multimedia release go to:
https://www.multivu.com/players/English/8068751-alcon-pharmaceuticals-my-cataracts-eye-care/
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
With the flip of a switch on Thursday, the largest solar panel array in New Jersey will come to life on the campus of Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., as company leaders and employees inaugurate the largest solar installation of any site among the Johnson & Johnson Family of Companies around the world.
To view Multimedia News Release, go to http://multivu.pACrnewswire.com/mnr/janssen/45911/
Society for Science & the Public (Society) today announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is the new title sponsor of the Science Talent Search. Selected through a competitive process that garnered interest from the nation’s leading companies and philanthropists, Regeneron will become only the third sponsor in 75 years of the nation’s oldest and most prestigious high school science competition.
The new sponsorship will be celebrated at a special event today at the American Museum of Natural History, which is known for its extensive science education program. The event will be hosted by astrophysicist Neil deGrasse Tyson, Ph.D., Frederick P. Rose director of the Hayden Planetarium at the American Museum of Natural History, and can be viewed via webcast at 9:00 a.m. EDT at http://edge.media-server.com/m/go/sciencetalentsearch.
Regeneron is committing $100 million to support the Science Talent Search and other Society programs through 2026 and will assume title sponsorship of the competition effectively immediately. As part of its commitment, Regeneron is nearly doubling the overall award distribution to $3.1 million annually, increasing the top award to $250,000, and doubling the awards for the top 300 young scientists and their schools to $2,000 each. During its history, the Science Talent Search has provided more than $25 million in awards to over 8,500 students and schools.
To view the multimedia release go to:
http://www.multivu.com/players/English/7846351-regeneron-science-talent-search/
Takeda today announced the launch of a new expert Report on COPD, introduced at a Takeda organised press conference on the occasion of the 2012 European Respiratory Society (ERS) Annual Congress taking place from 1- 5 September in Vienna, Austria.
The Report, entitled ‘The Shifting Paradigm in Chronic Obstructive Pulmonary Disease (COPD) Management,’ was initiated and developed by Takeda Pharmaceuticals International GmbH and is a compilation of opinion articles from a panel of key international respiratory experts, the European Federation of Allergy and Airways Diseases Patients’ Association (EFA) and COPD patients, reflecting updated guidance and research. The new expert Report was developed in response to a recent shift in emphasis in COPD management which now places future risk at equal importance to treatment of current disability. Treatment objectives are now divided into two groups: reducing symptoms and reducing risk.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56582-expert-report-on-copd-launch
Patients and scientists from across the country are featured in the latest “From Hope to Cures” ad campaign launched today by the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents the country’s leading biopharmaceutical researchers and biotechnology companies.
This continuation of PhRMA’s “From Hope to Cures” campaign, first launched in January 2014, highlights the value biopharmaceutical innovation provides to patients, society and the economy. The latest ad campaign, featuring print, radio and digital advertising, highlights the stories of patients who benefit from the medicines developed by biopharmaceutical companies and the scientists who work every day to develop life-saving treatments and cures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350552-phrma-from-hope-to-cures/
Results from a large retrospective data analysis published in the American Journal of Transplantation (AJT) today, showed that liver transplantation patients who were treated early with Advagraf experienced a significantly increased graft survival benefit of 8% at 3 years post-transplant compared with patients treated with the current standard of care, tacrolimus immediate release (twice daily).
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7451251-advagraf-prolonged-release-tacrolimus/
As the rate of teen prescription drug abuse continues to rise in the United States, the National Association of School Nurses (NASN) and Janssen Pharmaceuticals, Inc., today joined with addiction expert Dr. Drew Pinsky,* to launch a new tool kit intended to help America’s schools educate teens and their parents about the risks and consequences of abusing prescription medication.
The Schools Get Smart, Schools Take Action Tool Kit is part of Smart Moves, Smart Choices, a national initiative of NASN and Janssen Pharmaceuticals, Inc., designed to inform parents, teens and educators about this growing problem of teen prescription drug abuse, and what they can do to combat it.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/smartmovessmartchoices/51444/
